$316 Million is the total value of First Light Asset Management, LLC's 52 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEO | Sell | NEOGENOMICS INC | $26,800,000 | +11.6% | 2,407,930 | -10.1% | 8.49% | +5.4% |
| IMMU | Sell | IMMUNOMEDICS INC | $18,335,000 | +1.4% | 1,311,514 | -36.0% | 5.81% | -4.3% |
| XENT | Sell | INTERSECT ENT INC | $5,302,000 | -30.7% | 170,197 | -37.8% | 1.68% | -34.6% |
| LHCG | Sell | LHC GROUP INC | $4,587,000 | -26.5% | 64,672 | -29.6% | 1.45% | -30.6% |
| STRM | Sell | STREAMLINE HEALTH SOLUTIONS | $2,588,000 | +36.5% | 1,760,706 | -0.6% | 0.82% | +28.9% |
| ENZ | Sell | ENZO BIOCHEM INC | $2,362,000 | -46.9% | 225,616 | -44.0% | 0.75% | -49.9% |
| TEAR | Exit | TEARLAB CORP | $0 | – | -420,066 | -100.0% | -0.24% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -114,702 | -100.0% | -0.64% | – |
| AMED | Exit | AMEDISYS INC | $0 | – | -92,535 | -100.0% | -1.95% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -92,761 | -100.0% | -2.48% | – |
| SPNC | Exit | SPECTRANETICS CORP | $0 | – | -217,637 | -100.0% | -2.80% | – |
| AKRXQ | Exit | AKORN INC | $0 | – | -732,462 | -100.0% | -8.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.